February 21, 2024 07:23 AM ESTUpdated February 22, 04:12 AM
R&D

Bavar­i­an Nordic drops can­cer vac­cine ef­forts to fo­cus on in­fec­tious dis­eases

Ayisha Sharma

News Reporter

Bavar­i­an Nordic will no longer work on its im­muno-on­col­o­gy vac­cine pro­gram to in­stead fo­cus on in­fec­tious dis­ease R&D, with the com­pa­ny’s “record” 2023 sales buoyed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times